Why the study?
Superficial vein thrombosis has historically been considered benign and excluded from major studies, but untreated cases can cause DVT or PE, creating a need for evidence-based guidance on its diagnosis and management in pregnancy.
This position paper provides updated evidence-based recommendations for managing superficial venous thrombosis during pregnancy, a condition increasingly recognized for its potential to cause DVT or PE if untreated.
SVT in pregnancy may warrant closer scrutiny; leaves open optimal anticoagulation strategies.
Venous thromboembolism (VTE) is a multifactorial disease that can possibly affect any part of venous circulation. The risk of VTE increases by about 2 fold in pregnant women and VTE is one of the major causes of maternal morbidity and mortality. For decades superficial vein thrombosis (SVT) has been considered as benign, self-limiting condition, primarily local event consequently being out of scope of well conducted epidemiological and clinical studies. Recently, the approach on SVT has significantly changed considering that prevalence of lower limb SVT is twice higher than both deep vein thrombosis (DVT) and pulmonary embolism (PE). The clinical severity of SVT largely depends on the localization of thrombosis, when it concerns the major superficial vein vessels of the lower limb and particularly the great saphenous vein. If untreated or inadequately treated, SVT can potentially cause DVT or PE. The purpose of this review is to discuss the complex interconnection between SVT and risk factors in pregnancy and to provide evidence-based considerations, suggestions, and recommendations for the diagnosis and treatment of this precarious and delicate clinical entity.
No takes yet. Share an insight, caveat, or question.
Antić et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: